Ordering Recommendation

Assess risk of ovarian cancer in women who present with an adnexal mass.

Mnemonic
OVA1 PLUS
Methodology

Electrochemiluminescent Immunoassay (ECLIA)/Fixed-Rate-Time Nephelometry

Performed

Varies

Reported

4-8 days
N/A

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Serum Separator Tube (SST).

Specimen Preparation

Transfer 2.2 mL serum to an ARUP Standard Transport Tube. (Min: 1.1 mL)

Storage/Transport Temperature

Frozen. Also acceptable: Refrigerated.

Unacceptable Conditions
Remarks
Stability

Ambient: Unacceptable; Refrigerated: 8 days; Frozen: 9 weeks

Reference Interval

By Report

Interpretive Data



No compliance statements are in use for this test.

Note

OVA1 Biomarkers: CA-125 II, Apoliproprotein A1 (Apo A-1), Beta-2 Microglobulin (B2M), Transferrin, and Prealbumin.

OVERA Biomarkers: Apolipoprotein A1 (Apo A-1), HE4 (Human Epididymis protein 4), CA-125 II, FSH (Follicle Stimulating Hormone), and Transferrin.

Hotline History
N/A
CPT Codes

81503

Components
Component Test Code* Component Chart Name LOINC
3002310 EER Malignancy Assessment, OVA1 Plus
3002311 Malignancy Assessment, Menopausal Status
3002312 Malignancy Assessment, CA 125 II
3002313 Malignancy Assessment, OVA1 Score
3002615 Malignancy Assessment, OVERA Score
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
Malignancy Risk Assessment, Pelvic Mass, OVA1 Plus

ASPiRA Labs, Inc